Evidence map›Paper›PMID 24112096›Full record

Trial reportThe American journal on addictions

The relationship between primary prescription opioid and buprenorphine-naloxone induction outcomes in a prescription opioid dependent sample.

Suzanne Nielsen, Maureen Hillhouse, Roger D Weiss, Larissa Mooney, Jennifer Sharpe Potter, Joshua Lee, Marc N Gourevitch, Walter Ling

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The American journal on addictions. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. French-Canadian Translation and Cultural Adaptation of the Clinical Opiate Withdrawal Scale: The COWS-FC.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2022
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Suzanne NielsenUCLA Integrated Substance Abuse Programs, Los Angeles, California; University of Sydney, Camperdown, New South Wales, Australia.
Maureen Hillhouse
Roger D Weiss
Larissa Mooney
Jennifer Sharpe Potter
Joshua Lee
Marc N Gourevitch
Walter Ling

Funding

Project-004UG1DA020024 · NIDA · UT SOUTHWESTERN MEDICAL CENTER · PI Steven J Shoptaw, MADHUKAR H. TRIVEDI · 2015 to 2026
$71.6M
The National Drug Abuse Treatment Clinical Trials NetworkU10DA013045 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LING, WALTER NMN · 1999 to 2015
$52.6M
CU PARTNERS: NY/LONG ISLAND REGIONAL NODEU10DA013035 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI NUNES, EDWARD V., ROTROSEN, JOHN P · 2001 to 2015
$47.6M
Clinical Trials Network, Ohio Valley Node U10DA013732U10DA013732 · NIDA · UNIVERSITY OF CINCINNATI · PI WINHUSEN, T JOHN · 2000 to 2015
$45.0M
Southern Consortium Node of the Clinical Trials NetworkU10DA013727 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRADY, KATHLEEN T. · 2000 to 2015
$34.4M
The National Drug Abuse Treatment Clinical Trials Network (U10)U10DA015831 · NIDA · MC LEAN HOSPITAL (BELMONT, MA) · PI CARROLL, KATHLEEN M., WEISS, ROGER D. · 2002 to 2015
$28.8M
CLINICAL TRIALS NETWORK: PACIFIC NORTHWEST NODEU10DA013714 · NIDA · UNIVERSITY OF WASHINGTON · PI DONOVAN, DENNIS MICHAEL, ROLL, JOHN M. · 2001 to 2015
$25.5M
Western States Node of the National Drug Abuse Treatment Clinical Trials NetworkU10DA015815 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MCCARTY, DENNIS, SORENSEN, JAMES L · 2002 to 2015
$25.2M
Concept ProjectU10DA020024 · NIDA · UT SOUTHWESTERN MEDICAL CENTER · PI TRIVEDI, MADHUKAR H. · 2005 to 2015
$22.6M
CLINICAL TRIAL RESEARCH PROJECT COREU10DA020036 · NIDA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DALEY, DENNIS C · 2005 to 2015
$14.1M
Mentoring in Drug Abuse and Dual Diagnosis ResearchK24DA022288 · NIDA · MCLEAN HOSPITAL · PI WEISS, ROGER D. · 2007 to 2016
$1.8M
Role of Buprenorphine in Improving Clinical Care in Opioid Addiction and HIVK24DA023359 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MCCANCE-KATZ, ELINORE F. · 2007 to 2011
$918k
NHLBI NIH HHS HHSN2712005220HCNIDA NIH HHS 2U10DA013035NIDA NIH HHS 2U10DA013045NIDA NIH HHS 2U10DA013714NIDA NIH HHS 2U10DA013727NIDA NIH HHS 2U10DA015815NIDA NIH HHS 2U10DA015831NIDA NIH HHS 2U10DA020036NIDA NIH HHS 5U10DA013732NIDA NIH HHS K23 DA022297NIDA NIH HHS K24 DA022288NIDA NIH HHS K24 DA023359NIDA NIH HHS K24DA023359NIDA NIH HHS U10 DA013035NIDA NIH HHS U10 DA013045NIDA NIH HHS U10 DA013714NIDA NIH HHS U10 DA013727NIDA NIH HHS U10 DA013732NIDA NIH HHS U10 DA015815NIDA NIH HHS U10 DA015831NIDA NIH HHS U10 DA020024NIDA NIH HHS U10 DA020036NIDA NIH HHS UG1 DA020024PHS HHS HHSN271200522081C
6 · The paper itself

Abstract

BACKGROUND AND

objectivesThis analysis aims to: (1) compare induction experiences among participants who self-reported using one of the four most commonly reported POs, and (2) examine factors associated with difficult bup-nx induction. Our hypothesis, based on previous research and current guidelines, is that those on longer-acting opioids will have experienced more difficult inductions.

methodsThe Prescription Opioid Addiction Treatment Study (POATS) was a multi-site, randomized clinical trial, using a two-phase adaptive treatment research design. This analysis examines bup-nx induction of participants who self-reported primary PO use of methadone, ER-oxycodone, IR-oxycodone, and hydrocodone (n = 69). Analyses examined characteristics associated with difficult induction, defined as increased withdrawal symptoms measured by the Clinical Opiate Withdrawal Scale (COWS) after the first bup-nx dose with higher scores denoting greater withdrawal symptoms/severity.

resultsContrary to our hypothesis, difficult induction experiences did not differ by primary PO type. Those who experienced a post-induction increase in COWS score had lower pre-dose COWS scores compared to those who did not experience a post-induction increase in COWS score (10.09 vs. 12.77, t(624) = -13.56, p < .001). Demographics characteristics, depression, and pain history did not predict a difficult induction. CONCLUSIONS AND SCIENTIFIC SIGNIFICANCE: Difficult bup-nx inductions were not associated with participants' primary PO. Severity of withdrawal, measured with the COWS, was an important variable, reminding clinicians that bup-nx should not be commenced prior to evidence of moderate opioid withdrawal. These findings add to the evidence that with careful procedures, bup-nx can used with few difficulties in PO-dependent patients. (Am J Addict 2014;23:343-348).

Indexed as

AdultAnalgesics, OpioidBuprenorphineDelayed-Action PreparationsFemaleHumansMaleNaloxoneNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersPrescription DrugsTreatment OutcomeYoung AdultAnalgesics, OpioidBuprenorphineDelayed-Action PreparationsNaloxoneNarcotic AntagonistsPrescription Drugsbuprenorphineinductionprescription opioid dependence

Identifiers

PMID24112096
PMCPMC4151625

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.